Navigation Links
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
Date:6/29/2009

MISSISSAUGA, ON, June 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that YM's subsidiary, CIMYM BioSciences Inc. and Oncoscience AG have resolved the issues between the companies in a cooperative effort. CIMYM BioSciences has formally notified Oncoscience that it no longer intends to submit its application to the London Court of International Arbitration for resolution of the matters previously in dispute.

"We are pleased that CIMYM BioSciences and Oncoscience have resolved their differences amicably at a minimal cost to either party and that each are committed to cooperate fully in moving nimotuzumab forward clinically with all due deliberate speed," said David Allan, Chairman and CEO of YM BioSciences. "The late-stage European clinical program Oncoscience is undertaking contributes significantly to the broad program being advanced by the network of cooperative relationships dedicated to the development of this important cancer drug globally."

"Its unique safety profile and efficacy make nimotuzumab a very promising and innovative treatment option with the potential to maintain a high quality of life for patients suffering from a number of different cancer indications," added Ferdinand Bach, CEO of Oncoscience. "I am delighted that we may now focus our combined resources exclusively on the contribution to the clinical program being undertaken globally for this promising drug. Recruitment of our Phase III trial in newly diagnosed pediatric pontine glioma has been concluded and we anticipate that recruitment in our randomised Phase III trial in adult glioblastoma grade IV will be completed in 2009. We are confident that data from these tri
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... will improve efficiency of their entire waste to energy process and continue to ... Gets a Major Upgrade , Temarry’s Waste to Energy process has been operating ...
(Date:9/1/2015)... September 2, 2015 ... die Forschung und Entwicklung neuartiger Therapien für ... Darmerkrankungen und Reizdarm konzentriert, erhält vom US ... sein neues Medikament patentiert wird. Das Medikament ... bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... Global Investment Conference sponsored by H.C. Wainwright ... St. Regis Hotel in New York, NY ... Chief Executive Officer, will provide an overview of the ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Panel discussion with Georgetown experts to address biotechnology, science, ... , , ... the National Institutes of Health and the Food and Drug Administration ... personalized medicine -- treatments tailored to match a person,s genetic make-up.  Significant ...
... ... in natural resource use in the 2009 Corporate Sustainability Report. , ... Madison, WI USA (PRWEB) June 22, ... Corporate Sustainability Report . This report summarizes Promega goals and accomplishments to conserve natural ...
... A team of researchers from the University of Alberta and ... of an unsealed plastic solar cell, from mere hours to ... inexpensive, readily available plastic solar cell technology hit a wall ... the prototype. A chemical coating on an electrode was unstable ...
Cached Biology Technology:Pebbles Along the 'Path' to Personalized Medicine 2Pebbles Along the 'Path' to Personalized Medicine 3Pebbles Along the 'Path' to Personalized Medicine 4Promega Releases 2009 Corporate Sustainability Report 2
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... 2015  Based on its recent analysis of the biometric ... African Biometrics Company of the Year Award. DERMALOG is the ... in Africa . It has particularly gained ... implemented one of the largest biometric mass applications in the ... Central Bank of Nigeria with its ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... scientists warned that the United States must be careful ... alternative to imported oil takes into account potential damage ... growth in biofuels production could have far-reaching environmental and ... and growing tension between energy and water security," said ...
... the latest American Chemical Society (ACS) Weekly PressPac from ... ACS, 34 peer-reviewed journals and Chemical & Engineering ... American Chemical Society as the source for this information.` ... FOR IMMEDIATE RELEASE New tests: Marijuana damages ...
... and New Zealand researchers have accelerated research into Multiple ... will help to unravel the causes of MS and ... be published today in the prestigious journal Nature ... has remained a mystery. This discovery reveals important new ...
Cached Biology News:Rice University researchers ask if biofuels will lead to a 'drink or drive' 2American Chemical Society weekly presspac -- June 10, 2009 2American Chemical Society weekly presspac -- June 10, 2009 3American Chemical Society weekly presspac -- June 10, 2009 4American Chemical Society weekly presspac -- June 10, 2009 5American Chemical Society weekly presspac -- June 10, 2009 6American Chemical Society weekly presspac -- June 10, 2009 7Aussie and Kiwi researchers make double MS genetic discovery 2
... derived from Trichoplusia ni egg cell ... capable of expressing significantly higher levels ... other insect cells. High Five cells ... as adherent cultures- Quick adaptation into serum-free ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
... Cell Medium is optimized for serum-free growth ... In this protein-free medium, Sf9 cultures routinely ... cells/ml with viabilities above 95%. This medium ... color from X-gluc staining of pBACgus recombinants ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
Biology Products: